Stock Markets February 12, 2026

ABPRO Shares Slide After Nasdaq Flags Board Independence Shortfalls

Nasdaq notifies biopharma firm of multiple listing-rule violations following two director resignations; company begins search for independent directors

By Priya Menon ABPR
ABPRO Shares Slide After Nasdaq Flags Board Independence Shortfalls
ABPR

ABPRO Holdings Inc. (NASDAQ:ABPR) saw its stock drop about 9.4% in premarket trading after Nasdaq informed the company that it is not meeting several listing standards related to board independence and audit and compensation committee composition following the January resignations of two directors. The exchange has asked the company to present its views to a Hearings Panel by February 12 and has given a separate cure period for compensation committee requirements tied to the next annual meeting or specified calendar dates. ABPRO says it is seeking to appoint qualified independent directors but warned there is no guarantee it will regain compliance or retain its listing.

Key Points

  • ABPRO shares fell about 9.4% in premarket trading after Nasdaq notified the company of multiple listing-rule violations.
  • Nasdaq said ABPRO no longer meets requirements for a majority of independent directors and at least three independent audit committee members following the January resignations of Anthony D. Eisenberg and Sooyoung Lee.
  • ABPRO has initiated a process to appoint qualified independent directors; Nasdaq has given a cure period for compensation committee composition tied to the next annual meeting or set calendar dates.

ABPRO Holdings Inc. (NASDAQ:ABPR) experienced a sharp premarket decline of 9.4% after disclosing that Nasdaq has delivered notices asserting the company is not in compliance with multiple listing requirements. The deficiencies stem from the resignation in January of two members of ABPRO’s board of directors, Anthony D. Eisenberg and Sooyoung Lee, who stepped down from the board and all committees.

According to the company’s disclosure, the departures left ABPRO without a majority of independent directors on its board and without the minimum of three independent members required on its audit committee under Nasdaq rules. Nasdaq informed the company on February 5 that these shortfalls represent "additional bases for delisting the Company’s securities," and it has asked ABPRO to submit its views to the Nasdaq Hearings Panel by February 12.

In a separate communication, the exchange said ABPRO no longer satisfies the rule requiring at least two independent directors on its compensation committee. For that particular violation, Nasdaq has provided a cure period that extends until the company’s next annual shareholders’ meeting or until January 30, 2027, or July 29, 2026 if the next annual meeting occurs before that date.

ABPRO stated that it has begun a process to identify and appoint qualified independent directors to remedy the governance deficiencies. The company noted, however, that the notices themselves do not cause an immediate change to its listing status. It also acknowledged there is "no assurance that the Panel will grant the Company’s request for continued listing" or that ABPRO will be able to regain compliance within the timeframes set by Nasdaq.

The governance shortfalls cited by Nasdaq relate specifically to the composition of the board and the membership thresholds for the audit and compensation committees. ABPRO’s response plans are focused on restoring the required independent director counts, while it awaits further action from the Nasdaq Hearings Panel.


Summary

Nasdaq has told ABPRO that it is out of compliance with several listing rules after the January resignations of two directors. The firm’s shares fell about 9.4% in premarket trade. Nasdaq has asked for the company’s views by February 12 and has provided a separate cure period for compensation committee composition linked to the next annual meeting or specified calendar deadlines. ABPRO is seeking qualified independent directors but warned there is no guarantee it will regain compliance or keep its listing.

Key points

  • ABPRO stock declined roughly 9.4% in premarket trading following Nasdaq notices about listing noncompliance.
  • Nasdaq cited failures to maintain a majority of independent directors and at least three independent audit committee members after two directors resigned in January.
  • The exchange also flagged a compensation committee composition violation, for which the company has been given a cure period tied to upcoming meeting dates; ABPRO is searching for qualified independent directors to address the gaps.

Risks and uncertainties

  • Potential delisting - Nasdaq indicated the compliance failures could constitute additional bases for delisting; the Hearings Panel's decision is uncertain.
  • Timing and ability to replace directors - while ABPRO has started the process to appoint independent directors, there is no assurance it will secure suitable candidates and regain compliance within required timeframes.
  • Market reaction - the stock's immediate decline reflects investor concern; continued uncertainty around governance and listing status could affect the company’s market perception.

Risks

  • Possible delisting action if the Nasdaq Hearings Panel does not grant continued listing - impacts the company's market access and shareholders.
  • Uncertainty over the company’s ability and timing to recruit qualified independent directors to restore compliance - impacts corporate governance and regulatory standing.
  • Negative market sentiment as reflected in the premarket stock decline, which could persist if governance issues are unresolved - impacts investor confidence in the biotech sector and small-cap listings.

More from Stock Markets

Chinese AI Stocks Rally as Investors Embrace Winners While U.S. Markets Worry Feb 21, 2026 Three Earnings Reports This Week Will Test the Durability of the AI Investment Theme Feb 21, 2026 Moscow Market Closes Flat as Select Large-Caps Offset Losses Feb 21, 2026 Honeywell Reconsiders Purchase of Johnson Matthey Catalyst Unit as Closing Obstacles Emerge Feb 21, 2026 Indigenous Occupation Halts Operations at Cargill’s Santarem Terminal Feb 21, 2026